Evaluation of the Anti-Viral Activity of Human Recombinant Interferon Lambda-1 against SARS-CoV-2

Мадонов, П. Г.; Svyatchenko, V. A.; Legostaev, S. S.; Kikhtenko, N. A.; Kotlyarova, A. A.; Oleinik, L. A.; Baikalov, German

doi:10.1007/s10517-021-05330-0

Cited by 5 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No effect of a single dose of PEG-IFN lambda in a small study (n=60). [ 223 , 224 ] Anakinra Recombinant human IL-1 receptor antagonist Anakinra did not improve outcomes in 116 patients with mild-to-moderate COVID-19 pneumonia in a multicenter, open-label, randomized clinical trial (CORIMUNO-ANA-1) [ 225 ] Vitamin D A recent Cochrane systematic review concluded that there is currently insufficient evidence to determine the benefits and harms of vitamin D supplementation as a treatment of COVID‐19. [ 226 ] …”

Section: Treatment Of Covid-19 In Patients With Chronic Liver Disease...mentioning

confidence: 99%

See 1 more Smart Citation

Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper

Marjot

Eberhardt

Böettler

et al. 2022

Journal of Hepatology

View full text Add to dashboard Cite

Section: Treatment Of Covid-19 In Patients With Chronic Liver Disease...mentioning

confidence: 99%

“…No effect of a single dose of PEG-IFN lambda in a small study (n=60). [223,224] Anakinra Recombinant human IL-1 receptor antagonist…”

Section: Inhaled Budesonidementioning

confidence: 99%

Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper

Marjot

Eberhardt

Böettler

et al. 2022

Journal of Hepatology

View full text Add to dashboard Cite

“…In addition, type III IFNs (IFNλs) have been shown to play a pivotal role during SARS-CoV-2 infection [ 10 ], and several studies have reported that type III IFNs show in vitro anti-SARS-CoV-2 effects [ 11 , 12 ]. Moreover, mucosal type III IFN response has been found to be impaired in severe COVID-19 patients [ 2 , 13 ], but other studies observed a detrimental role for type III IFNs in the lung repair process [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Alterations in the Expression of IFN Lambda, IFN Gamma and Toll-like Receptors in Severe COVID-19 Patients

et al. 2023

View full text Add to dashboard Cite

Contradictory results have been reported regarding interferon (IFN) lambda (λ1–3) and IFN gamma (γ) production in COVID-19 patients. To gain insight into the roles played by these IFNs in SARS-CoV-2 infection, IFNλ1–3 and IFNγ mRNA expression was evaluated in peripheral blood mononuclear cells (PBMCs) (n = 32) and in cells of paired bronchoalveolar lavages (BALs) (n = 12). Lower IFNλ1–3 values (p < 0.001 for IFNλ1 and 3 and p = 0.013 for IFNλ2) in the PBMCs of severely ill patients were found compared to healthy donors (n = 15). Reduced levels of IFNγ were also detected in patients’ PBMCs (p < 0.01) and BALs (p = 0.041) compared to healthy donors. The presence of secondary bacterial infections was associated with decreased IFNλ amounts in PBMCs (p = 0.001, p = 0.015 and p = 0.003, respectively) but increased concentrations of IFNλ3 (p = 0.022) in BALs. Patients with alterations in C-reactive protein, lactate dehydrogenase and D-dimer levels had decreased IFNλ1 and 3 (p = 0.003 and p < 0.001) and increased IFNγ (p = 0.08) in PBMCs. Analyzing Toll-like receptors (TLRs) involved in IFN production, we found that TLR3 was highly expressed (p = 0.033) in patients with bacterial superinfections, while TLR7 and 8 (p = 0.029 and p = 0.049) were reduced in BALs of deceased patients. Overall, severe COVID-19 might be characterized by dysregulation in IFNγ, IFNλ and TLR3, 7 and 8 production.

show abstract

“…The virus-protective effect of IFN-λ, particularly IFN-λ1 (IFN-λ1 or IL-29), is especially evident at the epithelial barriers [13]. IFN-λ1 exhibits significant and highly effective antiviral activity during both prevention of viral invasion and its eradication [3][4][5][6].…”

mentioning

confidence: 99%

Pharmacokinetic Parameters of Oral Pegylated IFN-λ1

et al. 2022

Self Cite

View full text Add to dashboard Cite

We studied the pharmacokinetics of a pegylated IFN-λ1 (PEG IFN-λ1) after its oral administration to rats in different therapeutic doses. The hypothesis on linear pharmacokinetics of PEG IFN-λ1 within the dose range of 2.6-7.8 μg/kg was confirmed, high for protein molecules bioavailability from 17.5 to 21%, the absence of intravascular deposition, and effective elimination with feces and urine (85 and 15% of the administered dose, respectively) were demonstrated. At the same time, the mean retention time for PEG IFN-λ1 in the circulation is 6.46-6.65 h and half-life is 3 h. These findings give ground for continuing experimental studies of PEG IFN-λ1 pharmacokinetics, in particular, tissue distribution of the drug.

show abstract

Evaluation of the Anti-Viral Activity of Human Recombinant Interferon Lambda-1 against SARS-CoV-2

Cited by 5 publications

References 6 publications

Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper

Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper

Alterations in the Expression of IFN Lambda, IFN Gamma and Toll-like Receptors in Severe COVID-19 Patients

Pharmacokinetic Parameters of Oral Pegylated IFN-λ1

Contact Info

Product

Resources

About